🇺🇸 FDA
Patent

US 9562217

Modalities for the treatment of degenerative diseases of the retina

granted A61KA61K35/12A61K35/30

Quick answer

US patent 9562217 (Modalities for the treatment of degenerative diseases of the retina) held by Astellas Institute for Regenerative Medicine expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Astellas Institute for Regenerative Medicine
Grant date
Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K35/12, A61K35/30, A61K35/36, A61K35/44